Cenobamate

Chemical formula: C₁₀H₁₀ClN₅O₂  Molecular mass: 267.67 g/mol 

Therapeutic indications

Cenobamate is indicated for:

Focal-onset seizures with or without secondary generalisation

Population group: only adults (18 years old or older)

Cenobamate is indicated for the adjunctive treatment of focal-onset seizures with or without secondary generalisation in adult patients with epilepsy who have not been adequately controlled despite a history of treatment with at least 2 anti-epileptic medicinal products.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Contraindications

Cenobamate is contraindicated in the following cases:

Familial short-QT syndrome

Short QT syndrome

Get recommendations

Factors such as age, gender, and health history are evaluated to create a personalized medication regimen.

Ask the Reasoner

Related medicines

Structured Product Labeling (SPL/PLR) 2020: XCOPRI Film-coated tablet
Summary of Product Characteristics (SPC) 2022: ONTOZRY Tablet / Film-coated tablet
< Previous: Overview
Next: Precautions >

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.

⇈